Antioxidants in Down syndrome

Biochimica et Biophysica Acta - Molecular Basis of Disease

Volumn 1822, Issue 5, 2012, Pages 657-663

  Lott, Ira T ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Alzheimer disease; Antioxidant; Antioxidant clinical trial; Down syndrome; Mitochondrial disorder; Oxidative stress

Indexed keywords

ALPHA TOCOPHEROL; AMYLOID BETA PROTEIN; AMYLOID PRECURSOR PROTEIN; APOLIPOPROTEIN E4; ASCORBIC ACID; BIOLOGICAL MARKER; COPPER ZINC SUPEROXIDE DISMUTASE; DSCR1 PROTEIN; DYRK1A PROTEIN; F ISOPROSTANE; FOLIC ACID; GELSOLIN; GLUTATHIONE PEROXIDASE; HOMOCYSTEINE; HYDROXYL RADICAL; ISOPROSTANE DERIVATIVE; MITOCHONDRIAL DNA; NITRIC OXIDE; PLACEBO; REACTIVE OXYGEN METABOLITE; THIOCTIC ACID; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR ETS 2; UNCLASSIFIED DRUG;

AEROBIC METABOLISM; AGING; ALZHEIMER DISEASE; AMYLOID PLAQUE; ANTIOXIDANT ACTIVITY; APOPTOSIS; BIOENERGY; BRAIN CELL; BRAIN DEVELOPMENT; CARBOXY TERMINAL SEQUENCE; CELL PROLIFERATION; CHROMOSOME 16; CHROMOSOME 21; COGNITION; DEVELOPMENT; DISORDERS OF MITOCHONDRIAL FUNCTIONS; DOG; DOWN SYNDROME; DRUG BLOOD LEVEL; GENE MUTATION; GENE OVEREXPRESSION; GENETIC ASSOCIATION; HUMAN; LIPID PEROXIDATION; NERVE CELL NECROSIS; NERVOUS SYSTEM DEVELOPMENT; NEUROFIBRILLARY TANGLE; NEUROPATHOLOGY; NONHUMAN; OUTCOME ASSESSMENT; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN FUNCTION; REVIEW; RISK BENEFIT ANALYSIS; RISK REDUCTION; TRANSCRIPTION REGULATION; TRANSGENIC MOUSE; TUMOR SUPPRESSOR GENE; VITAMIN SUPPLEMENTATION; WORKING MEMORY;

ANIMALS; ANTIOXIDANTS; DISEASE MODELS, ANIMAL; DOGS; DOWN SYNDROME; MICE; MITOCHONDRIA; OXIDATIVE STRESS;

EID: 84858154824     PISSN: 09254439     EISSN: 1879260X     Source Type: Journal    
DOI: 10.1016/j.bbadis.2011.12.010     Document Type: Review

References (112)

1. Hattori M., Fujiyama A., Taylor T.D., Watanabe H., Yada T., Park H.S., Toyoda A., Ishii K., Totoki Y., Choi D.K., Groner Y., Soeda E., Ohki M., Takagi T., Sakaki Y., Taudien S., Blechschmidt K., Polley A., Menzel U., Delabar J., Kumpf K., Lehmann R., Patterson D., Reichwald K., Rump A., Schillhabel M., Schudy A., Zimmermann W., Rosenthal A., Kudoh J., Schibuya K., Kawasaki K., Asakawa S., Shintani A., Sasaki T., Nagamine K., Mitsuyama S., Antonarakis S.E., Minoshima S., Shimizu N., Nordsiek G., Hornischer K., Brant P., Scharfe M., Schon O., Desario A., Reichelt J., Kauer G., Blocker H., Ramser J., Beck A., Klages S., Hennig S., Riesselmann L., Dagand E., Haaf T., Wehrmeyer S., Borzym K., Gardiner K., Nizetic D., Francis F., Lehrach H., Reinhardt R., Yaspo M.L. The DNA sequence of human chromosome 21. Nature 2000, 405:311-319.
2. Sturgeon X., Gardiner K.J. Transcript catalogs of human chromosome 21 and orthologous chimpanzee and mouse regions. Mamm. Genome 2011, 22:261-271.
3. Antonarakis S.E., Lyle R., Dermitzakis E.T., Reymond A., Deutsch S. Chromosome 21 and down syndrome: from genomics to pathophysiology, nature reviews. Genetics 2004, 5:725-738.
4. Helguera P., Pelsman A., Pigino G., Wolvetang E., Head E., Busciglio J. ets-2 promotes the activation of a mitochondrial death pathway in Down's syndrome neurons. J. Neurosci. 2005, 25:2295-2303.
5. Chang K.T., Min K.T. Drosophila melanogaster homolog of Down syndrome critical region 1 is critical for mitochondrial function. Nat. Neurosci. 2005, 8:1577-1585.
6. Salehi A., Faizi M., Belichenko P.V., Mobley W.C. Using mouse models to explore genotype-phenotype relationship in Down syndrome. Ment. Retard. Dev. Disabil. Res. Rev. 2007, 13:207-214.
7. Das I., Reeves R.H. The use of mouse models to understand and improve cognitive deficits in Down syndrome. Dis. Models Mech. 2011, 4:596-606.
8. Roubertoux P.L., Carlier M. Mouse models of cognitive disabilities in trisomy 21 (Down syndrome), American journal of medical genetics, part C. Semin. Med. Genet. 2010, 154C:400-416.
9. Salehi A., Delcroix J.D., Mobley W.C. Traffic at the intersection of neurotrophic factor signaling and neurodegeneration. Trends Neurosci. 2003, 26:73-80.
10. Kleschevnikov A.M., Belichenko P.V., Villar A.J., Epstein C.J., Malenka R.C., Mobley W.C. Hippocampal long-term potentiation suppressed by increased inhibition in the Ts65Dn mouse, a genetic model of Down syndrome. J. Neurosci. 2004, 24:8153-8160.
11. Kurt M.A., Kafa M.I., Dierssen M., Davies D.C. Deficits of neuronal density in CA1 and synaptic density in the dentate gyrus, CA3 and CA1, in a mouse model of Down syndrome. Brain Res. 2004, 1022:101-109.
12. Costa A.C., Grybko M.J. Deficits in hippocampal CA1 LTP induced by TBS but not HFS in the Ts65Dn mouse: a model of Down syndrome. Neurosci. Lett. 2005, 382:317-322.
13. Hyde L.A., Frisone D.F., Crnic L.S. Ts65Dn mice, a model for Down syndrome, have deficits in context discrimination learning suggesting impaired hippocampal function. Behav. Brain Res. 2001, 118:53-60.
14. Patterson D. Molecular genetic analysis of Down syndrome. Hum. Genet. 2009, 126:195-214.
15. Ishihara K., Amano K., Takaki E., Ebrahim A.S., Shimohata A., Shibazaki N., Inoue I., Takaki M., Ueda Y., Sago H., Epstein C.J., Yamakawa K. Increased lipid peroxidation in Down's syndrome mouse models. J. Neurochem. 2009, 110:1965-1976.
16. Shukkur E.A., Shimohata A., Akagi T., Yu W., Yamaguchi M., Murayama M., Chui D., Takeuchi T., Amano K., Subramhanya K.H., Hashikawa T., Sago H., Epstein C.J., Takashima A., Yamakawa K. Mitochondrial dysfunction and tau hyperphosphorylation in Ts1Cje, a mouse model for Down syndrome. Hum. Mol. Genet. 2006, 15:2752-2762.
17. Shichiri M., Yoshida Y., Ishida N., Hagihara Y., Iwahashi H., Tamai H., Niki E. alpha-Tocopherol suppresses lipid peroxidation and behavioral and cognitive impairments in the Ts65Dn mouse model of Down syndrome. Free Radic. Biol. Med. 2011, 50:1801-1811.
18. Lockrow J., Prakasam A., Huang P., Bimonte-Nelson H., Sambamurti K., Granholm A.C. Cholinergic degeneration and memory loss delayed by vitamin E in a Down syndrome mouse model. Exp. Neurol. 2009, 216:278-289.
19. Rueda N., Florez J., Martinez-Cue C. Effects of chronic administration of SGS-111 during adulthood and during the pre- and post-natal periods on the cognitive deficits of Ts65Dn mice, a model of Down syndrome. Behav. Brain Res. 2008, 188:355-367.
20. Mann D.M., Esiri M.M. The pattern of acquisition of plaques and tangles in the brains of patients under 50years of age with Down's syndrome. J. Neurol. Sci. 1989, 89:169-179.
21. Lott I.T., Head E. Alzheimer disease and Down syndrome: factors in pathogenesis. Neurobiol. Aging 2005, 26:383-389.
22. Wisniewski K.E., Wisniewski H.M., Wen G.Y. Occurrence of neuropathological changes and dementia of Alzheimer's disease in Down's syndrome. Ann. Neurol. 1985, 17:278-282.
23. Kedziora J., Bartosz G. Down's syndrome: a pathology involving the lack of balance of reactive oxygen species. Free Radic. Biol. Med. 1988, 4:317-330.
24. Busciglio J., Andersen J.K., Schipper H.M., Gilad G.M., McCarty R., Marzatico F., Toussaint O. Stress, aging, and neurodegenerative disorders, molecular mechanisms. Ann. N. Y. Acad. Sci. 1998, 851:429-443.
25. Lott I.T., Head E., Doran E., Busciglio J. Beta-amyloid, oxidative stress and down syndrome. Curr. Alzheimer Res 2006, 3:521-528.
26. Reynolds G.P., Cutts A.J. Free radical damage in Down's syndrome brain. Biochem. Soc. Trans. 1993, 21:221S.
27. Brooksbank B.W., Martinez M., Balazs R. Altered composition of polyunsaturated fatty acyl groups in phosphoglycerides of Down's syndrome fetal brain. J. Neurochem. 1985, 44:869-874.
28. Odetti P., Angelini G., Dapino D., Zaccheo D., Garibaldi S., Dagna-Bricarelli F., Piombo G., Perry G., Smith M., Traverso N., Tabaton M. Early glycoxidation damage in brains from Down's syndrome. Biochem. Biophys. Res. Commun. 1998, 243:849-851.
29. Busciglio J., Yankner B.A. Apoptosis and increased generation of reactive oxygen species in Down's syndrome neurons in vitro. Nature 1995, 378:776-779.
30. Head E., Garzon-Rodriguez W., Johnson J.K., Lott I.T., Cotman C.W., Glabe C. Oxidation of Abeta and plaque biogenesis in Alzheimer's disease and Down syndrome. Neurobiol. Dis. 2001, 8:792-806.
31. Mecocci P., MacGarvey U., Beal M.F. Oxidative damage to mitochondrial DNA is increased in Alzheimer's disease. Ann. Neurol. 1994, 36:747-751.
32. Smith M.A., Perry G., Richey P.L., Sayre L.M., Anderson V.E., Beal M.F., Kowall N. Oxidative damage in Alzheimer's. Nature 1996, 382:120-121.
33. Busciglio J., Pelsman A., Helguera P., Ashur-Fabian O., Pinhasov A., Brenneman D.E., Gozes I. NAP and ADNF-9 protect normal and Down's syndrome cortical neurons from oxidative damage and apoptosis. Curr. Pharm. Des. 2007, 13:1091-1098.
34. Wu Z., Zhao Y., Zhao B. Superoxide anion, uncoupling proteins and Alzheimer's disease. J. Clin. Biochem. Nutr. 2010, 46:187-194.
35. Young K.J., Bennett J.P. The mitochondrial secret(ase) of Alzheimer's disease. J. Alzheimer's Dis. 2010, 20(Suppl 2):S381-S400.
36. Korenberg J.R., Kawashima H., Pulst S.M., Ikeuchi T., Ogasawara N., Yamamoto K., Schonberg S.A., West R., Allen L., Magenis E., et al. Molecular definition of a region of chromosome 21 that causes features of the Down syndrome phenotype. Am. J. Hum. Genet. 1990, 47:236-246.
37. Szymonik-Lesiuk S., Czechowska G., Stryjecka-Zimmer M., Slomka M., Madro A., Celinski K., Wielosz M. Catalase, superoxide dismutase, and glutathione peroxidase activities in various rat tissues after carbon tetrachloride intoxication. J. Hepato-Biliary-Pancreatic Surg. 2003, 10:309-315.
38. Badwey J.A., Karnovsky M.L. Active oxygen species and the functions of phagocytic leukocytes. Annu. Rev. Biochem. 1980, 49:695-726.
39. Akinci O., Mihci E., Tacoy S., Kardelen F., Keser I., Aslan M. Neutrophil oxidative metabolism in Down syndrome patients with congenital heart defects. Environ. Mol. Mutagen. 2010, 51:57-63.
40. Costa V., Sommese L., Casamassimi A., Colicchio R., Angelini C., Marchesano V., Milone L., Farzati B., Giovane A., Fiorito C., Rienzo M., Picardi M., Avallone B., Marco Corsi M., Sarubbi B., Calabro R., Salvatore P., Ciccodicola A., Napoli C. Impairment of circulating endothelial progenitors in Down syndrome. BMC Med. Genomics 2010, 3:40.
41. Moldrich R.X., Dauphinot L., Laffaire J., Vitalis T., Herault Y., Beart P.M., Rossier J., Vivien D., Gehrig C., Antonarakis S.E., Lyle R., Potier M.C. Proliferation deficits and gene expression dysregulation in Down's syndrome (Ts1Cje) neural progenitor cells cultured from neurospheres. J. Neurosci. Res. 2009, 87:3143-3152.
42. Borg J., Chereul E. Differential MRI patterns of brain atrophy in double or single transgenic mice for APP and/or SOD. J. Neurosci. Res. 2008, 86:3275-3284.
43. Macleod K., Leprince D., Stehelin D. The ets gene family. Trends Biochem. Sci. 1992, 17:251-256.
44. Wasylyk B., Hahn S.L., Giovane A. The Ets family of transcription factors. Eur. J. Biochem. 1993, 211:7-18. FEBS.
45. Yang A., Reeves R.H. Increased survival following tumorigenesis in Ts65Dn mice that model Down syndrome. Cancer Res. 2011, 71:3573-3581.
46. Reynolds L.E., Watson A.R., Baker M., Jones T.A., D'Amico G., Robinson S.D., Joffre C., Garrido-Urbani S., Rodriguez-Manzaneque J.C., Martino-Echarri E., Aurrand-Lions M., Sheer D., Dagna-Bricarelli F., Nizetic D., McCabe C.J., Turnell A.S., Kermorgant S., Imhof B.A., Adams R., Fisher E.M., Tybulewicz V.L., Hart I.R., Hodivala-Dilke K.M. Tumour angiogenesis is reduced in the Tc1 mouse model of Down's syndrome. Nature 2010, 465:813-817.
47. Rovelet-Lecrux A., Hannequin D., Raux G., Le Meur N., Laquerriere A., Vital A., Dumanchin C., Feuillette S., Brice A., Vercelletto M., Dubas F., Frebourg T., Campion D. APP locus duplication causes autosomal dominant early-onset Alzheimer disease with cerebral amyloid angiopathy. Nat. Genet. 2006, 38:24-26.
48. Prasher V.P., Farrer M.J., Kessling A.M., Fisher E.M., West R.J., Barber P.C., Butler A.C. Molecular mapping of Alzheimer-type dementia in Down's syndrome. Ann. Neurol. 1998, 43:380-383.
49. Schupf N., Patel B., Silverman W., Zigman W.B., Zhong N., Tycko B., Mehta P.D., Mayeux R. Elevated plasma amyloid beta-peptide 1-42 and onset of dementia in adults with Down syndrome. Neurosci. Lett. 2001, 301:199-203.
50. Teller J.K., Russo C., DeBusk L.M., Angelini G., Zaccheo D., Dagna-Bricarelli F., Scartezzini P., Bertolini S., Mann D.M., Tabaton M., Gambetti P. Presence of soluble amyloid beta-peptide precedes amyloid plaque formation in Down's syndrome. Nature Med. 1996, 2:93-95.
51. Zawia N.H., Lahiri D.K., Cardozo-Pelaez F. Epigenetics, oxidative stress, and Alzheimer disease. Free Radic. Biol. Med. 2009, 46:1241-1249.
52. Crawford D.R., Leahy K.P., Abramova N., Lan L., Wang Y., Davies K.J. Hamster adapt78 mRNA is a Down syndrome critical region homologue that is inducible by oxidative stress. Arch. Biochem. Biophys. 1997, 342:6-12.
53. Ermak G., Cheadle C., Becker K.G., Harris C.D., Davies K.J. DSCR1(Adapt78) modulates expression of SOD1. FASEB J. 2004, 18:62-69.
54. Harris C.D., Ermak G., Davies K.J. Multiple roles of the DSCR1 (Adapt78 or RCAN1) gene and its protein product calcipressin 1 (or RCAN1) in disease, cellular and molecular life sciences. CMLS 2005, 62:2477-2486.
55. Baek K.H., Zaslavsky A., Lynch R.C., Britt C., Okada Y., Siarey R.J., Lensch M.W., Park I.H., Yoon S.S., Minami T., Korenberg J.R., Folkman J., Daley G.Q., Aird W.C., Galdzicki Z., Ryeom S. Down's syndrome suppression of tumour growth and the role of the calcineurin inhibitor DSCR1. Nature 2009, 459:1126-1130.
56. Liu F., Liang Z., Wegiel J., Hwang Y.W., Iqbal K., Grundke-Iqbal I., Ramakrishna N., Gong C.X. Overexpression of Dyrk1A contributes to neurofibrillary degeneration in Down syndrome. FASEB J. 2008, 22:3224-3233.
57. Arque G., de Lagran M.M., Arbones M.L., Dierssen M. Age-associated motor and visuo-spatial learning phenotype in Dyrk1A heterozygous mutant mice. Neurobiol. Dis. 2009, 36:312-319.
58. Guedj F., Sebrie C., Rivals I., Ledru A., Paly E., Bizot J.C., Smith D., Rubin E., Gillet B., Arbones M., Delabar J.M. Green tea polyphenols rescue of brain defects induced by overexpression of DYRK1A. PLoS One 2009, 4:e4606.
59. Santos R.X., Correia S.C., Wang X., Perry G., Smith M.A., Moreira P.I., Zhu X. Alzheimer's disease: diverse aspects of mitochondrial malfunctioning. Int. J. Clin. Exp. Pathol. 2010, 3:570-581.
60. Corder E.H., Saunders A.M., Strittmatter W.J., Schmechel D.E., Gaskell P.C., Small G.W., Roses A.D., Haines J.L., Pericak-Vance M.A. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science 1993, 261:921-923.
61. Patel A., Rees S.D., Kelly M.A., Bain S.C., Barnett A.H., Thalitaya D., Prasher V.P. Association of variants within APOE, SORL1, RUNX1, BACE1 and ALDH18A1 with dementia in Alzheimer's disease in subjects with Down syndrome. Neurosci. Lett. 2011, 487:144-148.
62. Chang S., ran Ma T., Miranda R.D., Balestra M.E., Mahley R.W. Huang, lipid- and receptor-binding regions of apolipoprotein E4 fragments act in concert to cause mitochondrial dysfunction and neurotoxicity. Proc. Natl. Acad. Sci. U. S. A. 2005, 102:18694-18699.
63. Abdul H.M., Sultana R., St Clair D.K., Markesbery W.R., Butterfield D.A. Oxidative damage in brain from human mutant APP/PS-1 double knock-in mice as a function of age. Free Radic. Biol. Med. 2008, 45:1420-1425.
64. Parker W.D., Filley C.M., Parks J.K. Cytochrome oxidase deficiency in Alzheimer's disease. Neurology 1990, 40:1302-1303.
65. Caspersen C., Wang N., Yao J., Sosunov A., Chen X., Lustbader J.W., Xu H.W., Stern D., McKhann G., Yan S.D. Mitochondrial Abeta: a potential focal point for neuronal metabolic dysfunction in Alzheimer's disease. FASEB J. 2005, 19:2040-2041.
66. Gibson G.E., Karuppagounder S.S., Shi Q. Oxidant-induced changes in mitochondria and calcium dynamics in the pathophysiology of Alzheimer's disease. Ann. N. Y. Acad. Sci. 2008, 1147:221-232.
67. Rhein V., Song X., Wiesner A., Ittner L.M., Baysang G., Meier F., Ozmen L., Bluethmann H., Drose S., Brandt U., Savaskan E., Czech C., Gotz J., Eckert A. Amyloid-beta and tau synergistically impair the oxidative phosphorylation system in triple transgenic Alzheimer's disease mice. Proc. Natl. Acad. Sci. U. S. A. 2009, 106:20057-20062.
68. Corral-Debrinski M., Horton T., Lott M.T., Shoffner J.M., McKee A.C., Beal M.F., Graham B.H., Wallace D.C. Marked changes in mitochondrial DNA deletion levels in Alzheimer brains. Genomics 1994, 23:471-476.
69. Jovanovic S.V., Clements D., MacLeod K. Biomarkers of oxidative stress are significantly elevated in Down syndrome. Free Radic. Biol. Med. 1998, 25:1044-1048.
70. Coskun P.E., Wyrembak J., Derbereva O., Melkonian G., Doran E., Lott I.T., Head E., Cotman C.W., Wallace D.C. Systemic mitochondrial dysfunction and the etiology of Alzheimer's disease and down syndrome dementia. J. Alzheimer's Dis. 2010, 20(Suppl 2):S293-S310.
71. Lu J., Esposito G., Scuderi C., Steardo L., Delli-Bovi L.C., Hecht J.L., Dickinson B.C., Chang C.J., Mori T., Sheen V. S100B and APP promote a gliocentric shift and impaired neurogenesis in Down syndrome neural progenitors. PLoS One 2011, 6:e22126.
72. Valenti D., Manente G.A., Moro L., Marra E., Vacca R.A. Deficit of complex I activity in human skin fibroblasts with chromosome 21 trisomy and overproduction of reactive oxygen species by mitochondria: involvement of the cAMP/PKA signalling pathway. Biochem. J. 2011, 435:679-688.
73. Dogliotti G., Galliera E., Dozio E., Vianello E., Villa R.E., Licastro F., Barajon I., Corsi M.M. Okadaic acid induces apoptosis in Down syndrome fibroblasts. Toxicol. in Vitro 2010, 24:815-821.
74. Infantino V., Castegna A., Iacobazzi F., Spera I., Scala I., Andria G., Iacobazzi V. Impairment of methyl cycle affects mitochondrial methyl availability and glutathione level in Down's syndrome. Mol. Genet. Metab. 2011, 102:378-382.
75. Aliev G., Li Y., Palacios H.H., Obrenovich M.E. Oxidative stress induced mitochondrial DNA deletion as a hallmark for the drug development in the context of the cerebrovascular diseases. Recent patents on cardiovascular drug discovery 2011, 6:222-241.
76. Strydom A., Dickinson M.J., Shende S., Pratico D., Walker Z. Oxidative stress and cognitive ability in adults with Down syndrome. Prog. Neuro-Psychopharmacolog. Biol. Psychiatry 2009, 33:76-80.
77. Campos C., Guzman R., Lopez-Fernandez E., Casado A. Urinary uric acid and antioxidant capacity in children and adults with Down syndrome. Clin. Biochem. 2010, 43:228-233.
78. Tiano L., Padella L., Carnevali P., Gabrielli O., Bruge F., Principi F., Littarru G.P. Coenzyme Q10 and oxidative imbalance in Down syndrome: biochemical and clinical aspects. Biofactors 2008, 32:161-167.
79. Il'yasova D., Kennedy K., Spasojevic I., Wang F., Tolun A.A., Base K., Young S.P., Kelly Marcom P., Marks J., Millington D.S., Dewhirst M.W. Individual responses to chemotherapy-induced oxidative stress. Breast Cancer Res. Treat. 2011, 125:583-589.
80. Uberos J., Romero J., Molina-Carballo A., Munoz-Hoyos A. Melatonin and elimination of kynurenines in children with Down's syndrome. J. Pediatr. Endocrinol. Metab. 2010, 23:277-282.
81. Meguid N.A., Dardir A.A., El-Sayed E.M., Ahmed H.H., Hashish A.F., Ezzat A. Homocysteine and oxidative stress in Egyptian children with Down syndrome. Clin. Biochem. 2010, 43:963-967.
82. Ji L., Chauhan V., Mehta P., Wegiel J., Mehta S., Chauhan A. Relationship between proteolytically cleaved gelsolin and levels of amyloid-beta protein in the brains of Down syndrome subjects. J. Alzheimer's Dis. 2010, 22:609-617.
83. Akomolafe A., Lunetta K.L., Erlich P.M., Cupples L.A., Baldwin C.T., Huyck M., Green R.C., Farrer L.A. Genetic association between endothelial nitric oxide synthase and Alzheimer disease. Clin. Genet. 2006, 70:49-56.
84. Sharma J.N., Al-Omran A., Parvathy S.S. Role of nitric oxide in inflammatory diseases. Inflammopharmacology 2007, 15:252-259.
85. Coppus A.W., Fekkes D., Verhoeven W.M., Tuinier S., Egger J.I., van Duijn C.M. Plasma amino acids and neopterin in healthy persons with Down's syndrome. J. Neural. Transm. 2007, 114:1041-1045.
86. Coppus A.M., Fekkes D., Verhoeven W.M., Tuinier S., van Duijn C.M. Plasma levels of nitric oxide related amino acids in demented subjects with Down syndrome are related to neopterin concentrations. Amino acids 2010, 38:923-928.
87. Hull M., Pasinetti G.M., Aisen P.S. Elevated plasma neopterin levels in Alzheimer disease. Alzheimer Dis. Assoc. Disord. 2000, 14:228-230.
88. Galasko D., Montine T.J. Biomarkers of oxidative damage and inflammation in Alzheimer's disease. Biomarkers Med. 2010, 4:27-36.
89. Sun Y.X., Minthon L., Wallmark A., Warkentin S., Blennow K., Janciauskiene S. Inflammatory markers in matched plasma and cerebrospinal fluid from patients with Alzheimer's disease. Dement. Geriatr. Cogn. Disord. 2003, 16:136-144.
90. Craggs L., Kalaria R.N. Revisiting dietary antioxidants, neurodegeneration and dementia. NeuroReport 2011, 22:1-3.
91. Petersen R.C., Thomas R.G., Grundman M., Bennett D., Doody R., Ferris S., Galasko D., Jin S., Kaye J., Levey A., Pfeiffer E., Sano M., van Dyck C.H., Thal L.J. Vitamin E and donepezil for the treatment of mild cognitive impairment. N. Engl. J. Med. 2005, 352:2379-2388.
92. Morris M.C., Evans D.A., Bienias J.L., Tangney C.C., Bennett D.A., Aggarwal N., Wilson R.S., Scherr P.A. Dietary intake of antioxidant nutrients and the risk of incident Alzheimer disease in a biracial community study. JAMA 2002, 287:3230-3237.
93. Engelhart M.J., Geerlings M.I., Ruitenberg A., van Swieten J.C., Hofman A., Witteman J.C., Breteler M.M. Dietary intake of antioxidants and risk of Alzheimer disease. JAMA 2002, 287:3223-3229.
94. Luchsinger J.A., Tang M.X., Shea S., Mayeux R. Antioxidant vitamin intake and risk of Alzheimer disease. Arch. Neurol. 2003, 60:203-208.
95. Laurin D., Masaki K.H., Foley D.J., White L.R., Launer L.J. Midlife dietary intake of antioxidants and risk of late-life incident dementia: the Honolulu-Asia Aging Study. Am. J. Epidemiol. 2004, 159:959-967.
96. Zandi P.P., Anthony J.C., Khachaturian A.S., Stone S.V., Gustafson D., Tschanz J.T., Norton M.C., Welsh-Bohmer K.A., Breitner J.C. Reduced risk of Alzheimer disease in users of antioxidant vitamin supplements: the Cache County Study. Arch. Neurol. 2004, 61:82-88.
97. Scarmeas N., Stern Y., Mayeux R., Luchsinger J.A. Mediterranean diet, Alzheimer disease, and vascular mediation. Arch. Neurol. 2006, 63:1709-1717.
98. Cotman C.W., Head E. The canine (dog) model of human aging and disease: dietary, environmental and immunotherapy approaches. J. Alzheimer's Dis. 2008, 15:685-707.
99. Head E., Pop V., Sarsoza F., Kayed R., Beckett T.L., Studzinski C.M., Tomic J.L., Glabe C.G., Murphy M.P. Amyloid-beta peptide and oligomers in the brain and cerebrospinal fluid of aged canines. J. Alzheimer's Dis. 2010, 20:637-646.
100. Sarasa L., Gallego C., Monleon I., Olvera A., Canudas J., Montanes M., Pesini P., Sarasa M. Cloning, sequencing and expression in the dog of the main amyloid precursor protein isoforms and some of the enzymes related with their processing. Neuroscience 2010, 171:1091-1101.
101. Araujo J.A., Greig N.H., Ingram D.K., Sandin J., de Rivera C., Milgram N.W. Cholinesterase inhibitors improve both memory and complex learning in aged beagle dogs. J. Alzheimer's Dis. 2011, 26:143-155.
102. Head E., Nukala V.N., Fenoglio K.A., Muggenburg B.A., Cotman C.W., Sullivan P.G. Effects of age, dietary, and behavioral enrichment on brain mitochondria in a canine model of human aging. Exp. Neurol. 2009, 220:171-176.
103. Cotman C.W., Head E., Muggenburg B.A., Zicker S., Milgram N.W. Brain aging in the canine: a diet enriched in antioxidants reduces cognitive dysfunction. Neurobiol. Aging 2002, 23:809-818.
104. Milgram N.W., Adams B., Callahan H., Head E., Mackay B., Thirlwell C., Cotman C.W. Landmark discrimination learning in the dog. Learn. Mem. 1999, 6:54-61.
105. Lott I.T., Doran E., Nguyen V.Q., Tournay A., Head E., Gillen D.L. Down syndrome and dementia: a randomized, controlled trial of antioxidant supplementation, part A. Am. J. Med. Genet. 2011, 155A:1939-1948.
106. Ellis J.M., Tan H.K., Gilbert R.E., Muller D.P., Henley W., Moy R., Pumphrey R., Ani C., Davies S., Edwards V., Green H., Salt A., Logan S. Supplementation with antioxidants and folinic acid for children with Down's syndrome: randomised controlled trial. BMJ 2008, 336:594-597.
107. Berchtold N.C., Castello N., Cotman C.W. Exercise and time-dependent benefits to learning and memory. Neuroscience 2010, 167:588-597.
108. Littbrand H., Stenvall M., Rosendahl E. Applicability and effects of physical exercise on physical and cognitive functions and activities of daily living among people with dementia: a systematic review. Am. J. Phys. Med. Rehabil. / Assoc. Acad. Phyciatrists 2011, 90:495-518.
109. Lazarov O., Mattson M.P., Peterson D.A., Pimplikar S.W., van Praag H. When neurogenesis encounters aging and disease. Trends Neurosci. 2010, 33:569-579.
110. Zambrano J.C., Marquina R., Sulbaran N., Rodriguez-Malaver A.J., Reyes R.A. Aerobic exercise reduced oxidative stress in saliva of persons with Down syndrome. Res. Sports Med. 2009, 17:195-203.
111. Rosety-Rodriguez M., Rosety I., Fornieles-Gonzalez G., Diaz A., Rosety M., Ordonez F.J. A 12-week aerobic training programme reduced plasmatic allantoin in adolescents with Down syndrome. Br. J. Sports Med. 2010, 44:685-687.
112. Wollen K.A. Alzheimer's disease: the pros and cons of pharmaceutical, nutritional, botanical, and stimulatory therapies, with a discussion of treatment strategies from the perspective of patients and practitioners. Altern. Med. Rev. 2010, 15:223-244.